5-fluorouracil-interferon-α2b adjuvant treatment of Dukes C colorectal cancer

摘要: PURPOSE: To determine whether interferon-α2bcan improve results of 5-fluorouracil adjuvant treatment Dukes C colorectal cancer patients, we compared the outcome patients receiving a fluorouracil-interferon combination to that historic controls treated with fluorouracil alone. METHODS: Fifty-seven were given 5-fluorouracil-interferon-α in2b from October 1986 September 1990. The those obtained in 51 consecutive at same institutions (5-FU) alone (used doses and schedule) between 1983 1986. main prognostic variables similar two groups. RESULTS: No life-threatening toxicity occurred either group. addition interferon (IFN) slighlty impaired tolerance treatment; however, dose IFN had be reduced only five discontinued one patient. Grade 3 4 myelotoxicity was rare not substantially different Interferon-related side effects (fever, flu-like syndrome, malaise,etc.)were frequent, but, general, mild or moderate. At time this analysis (July 1992), median followup 49 (range, 20–70) months group 5-FU + IFN, 86 68–103) There 17 recurrences 15 cancer-related deaths among combined treatment, 27 Both five-year relapse-free survival (65 percentvs.47 percent;P=0.043) causespecific (64 percentvs.46 percent;P=0.038) significantly better treatment. After correction for influence pretreatment variables, again afforded significant advantage terms both (P<0.01) overall (P<0.001). CONCLUSION: 5-FU-IFN-α2btreatment seems prognosis patients.